Discussion
urothelial cancer, TEAEs, TNBC, tumour, mCRPC
SOLID TUMOUR, TUMOUR
The dose-expansion part of this study was conducted in 180 patients with previously treated locally advanced or metastatic solid tumours, including cohorts of patients with either In the overall study population, the ORR was 20.0%, which was consistent with the results previously reported for the dose-escalation part of the study (20.4%) [Previous studies of combinations of PARP inhibitors with PD-(L)1 inhibitors have demonstrated antitumour activity in a variety of tumour types, including in patients with TNBC with The second highest ORR (30.4%) was seen in the EOC arm harbouring The ORR with pamiparib plus tislelizumab in the urothelial cancer cohort in the present study (28.6%) also appeared encouraging, and was similar to findings reported in the phase III KEYNOTE-045 trial of pembrolizumab as second-line therapy for advanced urothelial cancer (21.1%) [Compared with urothelial cancer, TNBC and EOC harbouring It is notable that patients with mCRPC in the present study had a median PFS of 10.4 months (95% CI: 4.3, 16.2) and a median OS of 21.2 months (95% CI: 10.5, NE), which were longer than observed in other treatment arms. For comparison, in a recent phase III trial, median PFS and OS of patients with mCRPC receiving olaparib monotherapy were reported to be 5.8 and 17.5 months, respectively [Overall, the safety profile of the pamiparib plus tislelizumab combination was manageable. The most commonly reported TEAEs were consistent with those reported for the combination in the phase Ia part of the study [As seen in the dose-escalation part of the study [The strengths of the study included the assessment of the pamiparib and tislelizumab combination in multiple tumour types, including cohorts with EOC and TNBC, with variability in In conclusion, pamiparib in combination with tislelizumab showed evidence of antitumour activity in patients with advanced solid tumours, particularly those with 